Nebenwirkungen · Retsevmo
Retsevmo 40 mg hard capsules Retsevmo 80 mg hard capsules · Abschnitt 4.8 · PDF-Seite 17–18
HOS-146876 · Präparat HOS-099572
17 (37.5%), than in patients <65 years of age (7.6%). In study LIBRETTO-431, the frequency of AE leading to discontinuation of selpercatinib was higher in patients ≥65-74 years (14.3%), 75-84 years (20.0%) than in patients <65 years (7.1%) of age. No patients ≥85 years of age discontinued selpercatinib due to AE. In LIBRETTO-531, the frequency of AE leading to discontinuation of selpercatinib was higher in patients 75-84 years (10%), and ≥65-74 years (7.7%) than in patients <65 years (3.5%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage cf58a7da6f42e3cc7bc46160250f4d2d4b1de56de8bfb11813d269280fb09250 · Zeichen 27951–28448 im Abschnitt